BrainStorm’s CEO Issues Annual Letter to Shareholders

  BrainStorm’s CEO Issues Annual Letter to Shareholders

Business Wire

NEW YORK & PETACH TIKVAH, Israel -- January 23, 2013

BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem
cell technologies for neurodegenerative diseases, announced today that its
CEO, Dr. Adrian Harel, has issued an Annual Letter to Shareholders summarizing
the company’s extremely significant developments of 2012:

Dear BrainStorm Shareholders,

2012 has been a pivotal year for BrainStorm, as the company has achieved the
most significant milestones since its inception. We’ve made dramatic progress
in our clinical trials, establishing the safety of NurOwn cells in a first
group of ALS patients and demonstrating promising indications of clinical
improvement in some patients. As a result we’ve been fast-tracked to a Phase
IIa preliminary efficacy trial after only one year of testing. We’ve also made
key advances in product development, and secured the largest amount of
financing in any single year of operations. I am proud to share with you the
major highlights of the past twelve months:

I. Clinical Trials Progress

In early June, we performed the 12^th ALS patient transplantation in our Phase
I/II clinical trial with NurOwn at Hadassah Medical Center in Jerusalem. In
July, we submitted a positive interim safety report to the Israeli Ministry of
Health (MOH) on the first 12 ALS patients in the study, demonstrating that
treatment was well-tolerated and that there were promising indications of
clinical improvement in some of the patients.

Just as we welcomed in 2013, the MOH approved acceleration to a Phase IIa
dose-escalating trial to further evaluate the safety and preliminary efficacy
of NurOwn treatment. In the Phase IIa trial, which we are launching this
month, a second group of 12 patients will receive combined intramuscular and
intrathecal administration of NurOwn cells in three cohorts, with increasing
doses. The study participants, who have already been recruited, will be
monitored for three to six months after transplantation.

In addition, preparations are well underway for a Phase II clinical trial in
the USA, scheduled for 2013, pending FDA approval.

II. Advances in Product Development

In December 2012, we signed a strategic agreement with Octane Biotech of
Kingston, Ontario, to jointly develop a proprietary bioreactor for production
scale-up of NurOwn. The customized bioreactor will enable us to significantly
increase our production capabilities by using a single clean room for multiple
patients, reducing costs and time. We are very excited to be working with
Octane, given their expertise in developing automated production processes for
mesenchymal cell therapy technologies. The project is currently being
launched.

This year we also developed an innovative method for cryopreservation, or
freezing, of cells, for long-term storage, and production of repeat patient
doses of NurOwn without the need for additional bone marrow aspirations.
Applying this approach in a pre-clinical study, we established the safety of
repeat doses of NurOwn in mice using frozen cells, an important step in the
regulatory approval process for repeat dosing in ALS patients. We believe that
repeat dosing is the key to the long-term clinical efficacy of NurOwn, and our
proprietary cryopreservation method will enable us to do so without having to
perform repeat bone marrow aspirations for each treatment.

III. Financing in Place

This year, the Company received funding from Israel’s Office of the Chief
Scientist (OCS) in the amount of $530,000 for the company’s R&D and clinical
program for NurOwn in ALS patients. In December, the OCS approved an annual
grant to BrainStorm for 2013, for the sixth straight year. The 2013 funding in
the amount of $800,000 will support our NurOwn clinical development program.
In addition, we were awarded a 3-year grant by the CIIRDF (Canada-Israel
Research & Development Program) to fund 50% of our budget in a CAD$1.3 million
collaboration with Octane Biotech on development of a customized bioreactor.

In July, the Company completed a public offering, raising gross proceeds of
approximately $5.75 million. Maxim Group LLC served as the lead placement
agent for the offering and Leader Underwriters (1993) Ltd. acted as a
sub-agent of the placement agent.

With cash reserves of approximately $4 million, we are ready to embark on our
R&D and clinical trials program for 2013.

Having made huge strides these past 12 months, we look forward to an even more
impressive year in 2013, as we forge ahead with further expansion of our
clinical program to the United States, continued advances in product
development, and ramping-up of our business activities towards
commercialization.

I thank you for your unwavering support.

Adrian Harel
CEO

About BrainStorm Cell Therapeutics, Inc.

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the
development of first-of-its-kind adult stem cell therapies derived from
autologous bone marrow cells for the treatment of neurodegenerative diseases.
The Company holds the rights to develop and commercialize its NurOwn
technology through an exclusive, worldwide licensing agreement with Ramot, the
technology transfer company of Tel Aviv University. For more information,
visit the company’s website at www.brainstorm-cell.com.

Safe Harbor Statement

Statements in this announcement other than historical data and information
constitute "forward-looking statements" and involve risks and uncertainties
that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ
materially from those stated or implied by such forward-looking statements.
Terms and phrases such as “may,” “should,” “would,” “could,” “will,” “expect,”
“likely,” “believe,” “plan,” “estimate,” “predict,” “potential,” and similar
terms and phrases are intended to identify these forward-looking statements.
The potential risks and uncertainties include, without limitation, risks
associated with BrainStorm's limited operating history, history of losses;
minimal working capital, dependence on its license to Ramot's technology;
ability to adequately protect the technology; dependence on key executives and
on its scientific consultants; ability to obtain required regulatory
approvals; and other factors detailed in BrainStorm's annual report on Form
10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These
factors should be considered carefully, and readers should not place undue
reliance on BrainStorm’s forward-looking statements. The forward-looking
statements contained in this press release are based on the beliefs,
expectations and opinions of management as of the date of this press release.
We do not assume any obligation to update forward-looking statements to
reflect actual results or assumptions if circumstances or management’s
beliefs, expectations or opinions should change, unless otherwise required by
law. Although we believe that the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee future results,
levels of activity, performance or achievements.

Contact:

BrainStorm Cell Therapeutics Inc. (OTC.QB: BCLI)
Dr. Adrian Harel, CEO
Phone: +972-3-9236384
info@brainstorm-cell.com
www.brainstorm-cell.com
 
Press spacebar to pause and continue. Press esc to stop.